
Changing champions for women in ophthalmology
Read about how building awareness, recognition and engagement of women in ophthalmology is paying off.

Read about how building awareness, recognition and engagement of women in ophthalmology is paying off.

Advanced Ophthalmic Innovations' Paul glaucoma implant (PGI) delivers sustained pressure-lowering with a favourable safety profile in refractory glaucoma, according to the first systematic review and

UK researchers have suggested a possible association between atrial fibrillation (AF) and age-related macular degeneration (AMD), highlighting their shared risk factors and overlapping pathophysiology

Tattoo-associated uveitis becoming a regular occurrence in Australia

A non-Chinese study of repeated low-level red-light (RLRL) therapy in combination with ortho-k found it effective and safe for myopia control in Caucasian children in Spain, supporting the potential g

The FDA has granted investigational device exemption approval to EyeYon Medical to begin a clinical study of EndoArt, the company’s synthetic endothelial implant for chronic corneal oedema. The I

The authors of a University of Auckland study say keratitis after corneal transplantation remains an important threat to graft survival, with infection episodes markedly increasing the likelihood of g

Who's who among the 56th RANZCO Congress graduation and awards ceremony

Interruptions to intravitreal anti-VEGF therapy for neovascular AMD occurred among more than a quarter of patients in an Italian study. The multicentre retrospective analysis, published in the B

Continuous positive airway pressure (CPAP) therapy produces short-term increases in intraocular pressure (IOP) in adults with obstructive sleep apnoea (OSA), according to a Singaporean systematic revi

Authors of an international study identified a distinct genetic signature underpinning reticular pseudodrusen, a high-risk subtype of age-related macular degeneration (AMD), which they said reinforces

Twelve-month real-world data demonstrated that switching from a first-generation VEGF inhibitor to brolucizumab (Beovu) achieved a clinically significant extension of the treatment interval in patient